Inconclusive diagnosis of cystic fibrosis after newborn screening.

نویسندگان

  • Chee Y Ooi
  • Carlo Castellani
  • Katherine Keenan
  • Julie Avolio
  • Sonia Volpi
  • Margaret Boland
  • Tom Kovesi
  • Candice Bjornson
  • Mark A Chilvers
  • Lenna Morgan
  • Richard van Wylick
  • Steven Kent
  • April Price
  • Melinda Solomon
  • Karen Tam
  • Louise Taylor
  • Kylie-Ann Malitt
  • Felix Ratjen
  • Peter R Durie
  • Tanja Gonska
چکیده

OBJECTIVES To prospectively study infants with an inconclusive diagnosis of cystic fibrosis (CF) identified by newborn screening (NBS; "CF screen positive, inconclusive diagnosis" [CFSPID]) for disease manifestations. METHODS Infants with CFSPID and CF based on NBS from 8 CF centers were prospectively evaluated and monitored. Genotype, phenotype, repeat sweat test, serum trypsinogen, and microbiology data were compared between subjects with CF and CFSPID and between subjects with CFSPID who did (CFSPID→CF) and did not (CFSPID→CFSPID) fulfill the criteria for CF during the first 3 years of life. RESULTS Eighty-two subjects with CFSPID and 80 subjects with CF were enrolled. The ratio of CFSPID to CF ranged from 1:1.4 to 1:2.9 in different centers. CFTR mutation rates did not differ between groups; 96% of subjects with CFSPID and 93% of subjects with CF had 2 mutations. Subjects with CFSPID had significantly lower NBS immunoreactive trypsinogen (median [interquartile range]:77 [61-106] vs 144 [105-199] μg/L; P < .0001) than did subjects with CF. Pseudomonas aeruginosa and Stenotrophomonas maltophilia were isolated in 12% and 5%, respectively, of subjects with CFSPID. CF was diagnosed in 9 of 82 (11%) subjects with CFSPID (genotype and abnormal sweat chloride = 3; genotype alone = 4; abnormal sweat chloride only = 2). Sweat chloride was abnormal in CFSPID→CF patients at a mean (SD) age of 21.3 (13.8) months. CFSPID→CF patients had significantly higher serial sweat chloride (P < .0001) and serum trypsinogen (P = .009) levels than did CFSPID→CFSPID patients. CONCLUSIONS A proportion of infants with CFSPID will be diagnosed with CF within the first 3 years. These findings underscore the need for clinical monitoring, repeat sweat testing at age 2 to 3 years, and extensive genotyping.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Optimization of the French cystic fibrosis newborn screening programme by a centralized tracking process

Objectives To evaluate the French cystic fibrosis newborn screening algorithm, based on data tracked by a centralized monitoring process, from 2002 to 2014. The programme aimed to attain European Standards in terms of positive predictive value, sensitivity, the ratio of screen positive patients diagnosed with cystic fibrosis to infants who screen positive but with inconclusive diagnosis (CFSPID...

متن کامل

Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis.

BACKGROUND A challenging problem arising from cystic fibrosis (CF) newborn screening is the significant number of infants with hypertrypsinaemia (HIRT) with sweat chloride levels in the intermediate range and only one or no identified CF-causing mutations. OBJECTIVES To investigate the diagnostic value for CF of assessing CF transmembrane conductance regulator (CFTR) protein function by measu...

متن کامل

Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation.

OBJECTIVE Cystic fibrosis (CF), caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, continues to present diagnostic challenges. Newborn screening and an evolving understanding of CF genetics have prompted a reconsideration of the diagnosis criteria. STUDY DESIGN To improve diagnosis and achieve standardized definitions worldwide, the CF Foundation convened a committ...

متن کامل

Inconclusive cystic fibrosis neonatal screening results: long-term psychosocial effects on parents.

AIM Cystic Fibrosis (CF) Newborn Screening occasionally identifies neonates where a CF diagnosis can neither be confirmed nor excluded. To assess how parents of these infants cope with this ambiguous situation. METHODS Parents of 11 children with Ambiguous Diagnosis (group AD) were compared with parents of 11 children diagnosed with CF through neonatal screening [group Cystic Fibrosis Diagnos...

متن کامل

Stratifying Cystic Fibrosis Risk for Newborn Screen Infants With Equivocal Sweat Chloride Levels.

Risk for Newborn Screen Infants With Equivocal Sweat Chloride Levels We read with interest the recent study by Ooi et al, which adds significantly to the recent literature guiding physicians on how to manage infants with equivocal sweat chloride (30–59 mmol/L, termed cystic fibrosis [CF] screen positive, inconclusive diagnosis [CFSPID]) identified through newborn screening. Nine (11%) of 82 sub...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Pediatrics

دوره 135 6  شماره 

صفحات  -

تاریخ انتشار 2015